Jung Y. Hong

Joo Hyun Park
Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 189 publications

Reply to: "Beyond Average Grams: Aldehyde Dehydrogenase 2*2 and Alcohol-Induced Young-Onset Pancreatic Cancer" and "Uncontrolled Prediabetes Confounding in the Association Between Alcohol Consumption and Young-Onset Pancreatic Cancer".

Reply to: "Beyond Average Grams: Aldehyde Dehydrogenase 2*2 and Alcohol-Induced Young-Onset Pancreatic Cancer" and "Uncontrolled Prediabetes Confounding in the Association Between Alcohol Consumption and Young-Onset Pancreatic Cancer".

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 07, 2026

Genomic Landscape of GNAQ and GNA11 Mutations in Metastatic Solid Tumors: A Real-World Data Analysis.

Genomic Landscape of GNAQ and GNA11 Mutations in Metastatic Solid Tumors: A Real-World Data Analysis.

Journal: JCO precision oncology

Published: July 06, 2026

Utility of the neutrophil-to-lymphocyte ratio extends to patients from East Asia.

Utility of the neutrophil-to-lymphocyte ratio extends to patients from East Asia.

Journal: The Journal of clinical investigation

Published: March 16, 2026

Integrative Molecular Analysis to Predict Clinical Benefit of Everolimus in Patients With Gastro-Entero-Pancreatic Neuroendocrine Tumors (GEP-NETs).

Integrative Molecular Analysis to Predict Clinical Benefit of Everolimus in Patients With Gastro-Entero-Pancreatic Neuroendocrine Tumors (GEP-NETs).

Journal: Cancer control : journal of the Moffitt Cancer Center

Published: March 06, 2026

Systemic therapy for combined hepatocellular-cholangiocarcinoma: a comprehensive review of chemotherapy, immunotherapy, and targeted therapy.

Systemic therapy for combined hepatocellular-cholangiocarcinoma: a comprehensive review of chemotherapy, immunotherapy, and targeted therapy.

Journal: Journal of liver cancer

Published: February 18, 2026

Real-World Prevalence and Structural Validation of the Canonical 9p21 MTAP-CDKN2A/B Deletion in Non-NSCLC Solid Tumors.

Real-World Prevalence and Structural Validation of the Canonical 9p21 MTAP-CDKN2A/B Deletion in Non-NSCLC Solid Tumors.

Journal: Cancers

Published: February 04, 2026

Threshold Dose-Response Association Between Alcohol Consumption and Risk of Young-Onset Pancreatic Cancer: A Nationwide Korean Cohort Study of Young Adults Age 20-39 Years.

Threshold Dose-Response Association Between Alcohol Consumption and Risk of Young-Onset Pancreatic Cancer: A Nationwide Korean Cohort Study of Young Adults Age 20-39 Years.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 23, 2026

Tailored proton beam therapy for hepatocellular carcinoma: Addressing unmet needs through a multidisciplinary approach.

Tailored proton beam therapy for hepatocellular carcinoma: Addressing unmet needs through a multidisciplinary approach.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 12, 2026

Parity and Risk of Pancreatic Cancer Among Premenopausal Women: A Nationwide Cohort Study.

Parity and Risk of Pancreatic Cancer Among Premenopausal Women: A Nationwide Cohort Study.

Journal: Mayo Clinic proceedings

Published: November 12, 2025

Prognostic factors in first-line atezolizumab-bevacizumab treatment of intermediate or advanced hepatocellular carcinoma.

Prognostic factors in first-line atezolizumab-bevacizumab treatment of intermediate or advanced hepatocellular carcinoma.

Journal: PloS one

Published: October 16, 2025

Efficacy of neoadjuvant FOLFIRINOX in resectable pancreatic cancer (NeoFOL-R): study protocol for an international, multicenter, prospective, randomized controlled trial.

Efficacy of neoadjuvant FOLFIRINOX in resectable pancreatic cancer (NeoFOL-R): study protocol for an international, multicenter, prospective, randomized controlled trial.

Journal: BMC cancer

Published: October 11, 2025

Safety and Efficacy of Combining Metastasis-Directed Stereotactic Ablative Radiation Therapy with Tyrosine Kinase Inhibitors Versus Immune Checkpoint Inhibitors in Metastatic Hepatocellular Carcinoma.

Safety and Efficacy of Combining Metastasis-Directed Stereotactic Ablative Radiation Therapy with Tyrosine Kinase Inhibitors Versus Immune Checkpoint Inhibitors in Metastatic Hepatocellular Carcinoma.

Journal: Cancer research and treatment

Published: September 05, 2025

Showing 1-12 of 189

Last Updated: 09/26/2026